×

Biotech and Pharmaceuticals Life Sciences

  • MENLO PARK, Calif. _ Corium International Inc. on Thursday reported a loss of $12.9 million in its fiscal fourth quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • LONDON, Nov 16- Battle lines are being drawn as the first gene therapy for an inherited condition nears the U.S. market, offering hope for people with a rare form of blindness and creating a cost dilemma for healthcare providers. However, the U.S. Institute for Clinical and Economic Review said this week "at a placeholder price of $1,000,000, the high cost makes this...

  • CAMBRIDGE, Mass. _ Proteostasis Therapeutics Inc. on Tuesday reported a loss of $14 million in its third quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 63 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • MENLO PARK, Calif. _ Molecular Templates Inc. on Tuesday reported a loss of $11 million in its third quarter. The Menlo Park, California- based company said it had a loss of 62 cents per share. Molecular Templates shares have risen 57 percent since the beginning of the year.

  • *FDA clears Fasrena for patients aged 12 years and older. LONDON, Nov 15- AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it. The U.S. Food and Drug Administration's decision to endorse benralizumab, which will be...

  • Seres Therapeutics hopes to become the first company to leverage this discovery through a collaboration with the MD Anderson Cancer Center in Texas and the Parker Institute for Cancer Immunotherapy that will see its microbe medicine tested in a clinical trial. The Cambridge, Massachusetts- based firm has an exclusive option to license patent rights under...

  • LAUSANNE, Switzerland _ AC Immune SA on Monday reported a loss of $9.1 million in its third quarter. On a per-share basis, the Lausanne, Switzerland- based company said it had a loss of 16 cents. AC Immune shares have dropped 12 percent since the beginning of the year.

  • AUSTIN, Texas _ Mirna Therapeutics Inc. on Monday reported a loss of $11.9 million in its third quarter. On a per-share basis, the Austin, Texas- based company said it had a loss of $1.66. This story was generated by Automated Insights using data from Zacks Investment Research.

  • THE WOODLANDS, Texas _ Repros Therapeutics Inc. on Monday reported a loss of $1.6 million in its third quarter. On a per-share basis, the The Woodlands, Texas- based company said it had a loss of 4 cents. This story was generated by Automated Insights using data from Zacks Investment Research.

  • GERMANTOWN, Md. _ Neuralstem Inc. on Monday reported a loss of $134,000 in its third quarter. On a per-share basis, the Germantown, Maryland- based company said it had a loss of 18 cents. This story was generated by Automated Insights using data from Zacks Investment Research.

  • LYNBROOK, N.Y. _ BioSpecifics Technologies Corp. on Friday reported third-quarter profit of $2.7 million. The Lynbrook, New York- based company said it had net income of 37 cents per share. BioSpecifics shares have fallen 21 percent since the beginning of the year.

  • SAN RAMON, Calif. _ Galena Biopharma Inc. on Thursday reported a loss of $6.1 million in its third quarter. On a per-share basis, the San Ramon, California- based company said it had a loss of 15 cents. This story was generated by Automated Insights using data from Zacks Investment Research.

  • NEW YORK _ Fortress Biotech Inc. on Thursday reported a loss of $27.1 million in its third quarter. The New York- based company said it had a loss of 67 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.

  • NEW YORK _ Synergy Pharmaceuticals Inc. on Thursday reported a loss of $48.9 million in its third quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share. Three analysts surveyed by Zacks expected $5.8 million.

  • LOS ANGELES _ Puma Biotechnology Inc. on Thursday reported a loss of $77.2 million in its third quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $2.75 per share. Three analysts surveyed by Zacks expected $3.4 million.

  • Nov 9- Dynavax Technologies Corp's hepatitis B vaccine won the U.S. Food and Drug Administration's approval on the third attempt and Chief Executive Eddie Gray told Reuters the company was open to, but not waiting for, a partner to market the drug. The two-dose vaccine, Heplisav-B, will be Dynavax's first drug to come to market and its approval comes after two FDA...

  • MORRIS PLAINS, N.J. _ Immunomedics Inc. on Thursday reported a loss of $118.7 million in its fiscal first quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 10 cents per share. Immunomedics shares have nearly tripled since the beginning of the year.

  • NEW YORK _ Stemline Therapeutics Inc. on Thursday reported a loss of $16.1 million in its third quarter. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 57 cents per share. Stemline Therapeutics shares have risen 24 percent since the beginning of the year.

  • Nov 9- Dynavax Technologies Corp's twice-rejected hepatitis B vaccine was approved by the U.S. Food and Drug Administration on Thursday, marking the drug developer's first regulatory approval. The two-dose vaccine, Heplisav-B, is designed to enhance the body's immune response to the hepatitis B virus in adults aged 18 years and older. A panel of independent...

  • CAMBRIDGE, Mass. _ Catabasis Pharmaceuticls Inc. on Thursday reported a loss of $7 million in its third quarter. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 34 cents per share. This story was generated by Automated Insights using data from Zacks Investment Research.